Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2NETWORK 2NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Sarcoma 1

Conditions

Glioblastoma 2Recurrence 1Gliosarcoma 1

Interventions

Magnetic Resonance Spectroscopy 111Specimen Handling 106Cyclophosphamide 95Radiotherapy 75pembrolizumab 71Cisplatin 68Nivolumab 66fludarabine 61Carboplatin 60Biopsy 51Radiosurgery 47Paclitaxel 44Radiation 42Standard of Care 40Gemcitabine 37Doxorubicin 36Rituximab 35venetoclax 34Dexamethasone 34Surveys and Questionnaires 31fludarabine phosphate 30Radiotherapy, Intensity-Modulated 30Cytarabine 30durvalumab 27Practice Guidelines as Topic 27Blood Specimen Collection 27Ipilimumab 26Etoposide 25Drug Therapy 25Surgical Procedures, Operative 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Lomustine × 30 days × Clear all
NCT05095376 2026-05-19

Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma

NRG Oncology

Phase 3 Active not recruiting
265 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

NCT03970447 2026-05-15

GBM AGILE

Global Coalition for Adaptive Research

Phase 2/3 Recruiting
2,250 enrolled
CNS

Glioblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡